Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study - Top-Institutions - MDSpire

Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study

  • By

  • Xue Ding

  • Zhengye Wang

  • Hong Zhang

  • Li Dai

  • Huaxing Ma

  • Guangxian Leng

  • Yunshan Yang

  • Yongjin Zhou

  • Siqi Luo

  • Qian Wang

  • Xiangren Jin

  • July 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The Affiliated Hospital of Guizhou Medical University
    The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou

    Key Differentiators

    • Oncology

  • #2

    Peking University Cancer Hospital & Institute
    Peking University Cancer Hospital & Institute

    Beijing, Beijing

    Key Differentiators

    • Oncology

  • #3

    Chinese Academy of Medical Sciences
    Chinese Academy of Medical Sciences

    Beijing, Beijing

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #5

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study

  • by Xue Ding, Zhengye Wang, Hong Zhang, Li Dai, Huaxing Ma, Guangxian Leng, Yunshan Yang, Yongjin Zhou, Siqi Luo, Qian Wang, Xiangren Jin

  • July 15, 2026

Related Content

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis

Limited discriminative performance of endoscopic deep learning for Helicobacter pylori status assessment in gastric cancer patients: a retrospective study